Niagen Bioscience
NAGE
162 hedge funds and large institutions have $296M invested in Niagen Bioscience in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 68 increasing their positions, 38 reducing their positions, and 24 closing their positions.
85% more call options, than puts
Call options by funds: $1.9M | Put options by funds: $1.03M
79% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 38
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
5% more funds holding
Funds holding: 155 → 162 (+7)
2.97% more ownership
Funds ownership: 36.84% → 39.8% (+3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less capital invested
Capital invested by funds: $418M → $296M (-$122M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$11.2M |
| 2 |
Millennium Management
New York
|
+$6.59M |
| 3 |
AG
Algert Global
San Francisco,
California
|
+$4.51M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$4.19M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$10.7M |
| 2 |
WCM
Woodson Capital Management
Greenwich,
Connecticut
|
-$7.21M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.37M |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
-$3.44M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$3.08M |
NAGE Hedge Fund Activity: Q3 2025 in Review
162 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q3 2025, worth a combined $296M — down 29% from $418M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new NAGE positions and 24 closed out — a net gain of 8 holders — while 68 added to existing stakes and 38 trimmed.
The largest buyer was UBS Group, adding an estimated $11.2M. The largest seller was D.E. Shaw & Co, cutting an estimated $10.7M.
- 162 institutional investors held Niagen Bioscience (NAGE) as of Q3 2025, up from 155 in Q2 2025.
- Funds reported $296M of Niagen Bioscience stock for Q3 2025, down 29% quarter-over-quarter.
- 32 funds opened new Niagen Bioscience positions in Q3 2025 and 24 closed out, a net change of +8 holders.
- The largest Niagen Bioscience buyer in Q3 2025 was UBS Group, an estimated $11.2M added.
- The largest Niagen Bioscience seller in Q3 2025 was D.E. Shaw & Co, an estimated $10.7M sold.
Based on aggregated 13F filings for Q3 2025.